Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. One of the major
clinical challenges is adequate diagnosis and treatment of central nervous system (CNS) …

The adoptive transfer of natural killer (NK) cells is an emerging therapy in the field of
immuno-oncology. In the last 3 decades, NK cells have been utilized to harness the anti …

Many hematologic malignancies are not curable with chemotherapy and require novel
therapeutic approaches. Chimeric antigen receptor (CAR) T-cell therapy is 1 such approach …

Acute lymphoblastic leukemia (ALL) is the most common malignant disease affecting
children. Although therapeutic strategies have improved, T-cell acute lymphoblastic …

Aim Outcomes of children with high-risk (HR) relapsed acute lymphoblastic leukaemia
(ALL)(N= 393), recruited to ALLR3 and ALL-REZ BFM 2002 trials, were analysed. Minimal …

T-cell acute lymphoblastic leukemia (T-ALL), a T-cell malignant disease that mainly affects
children, is still a medical challenge, especially for refractory patients for whom therapeutic …

* Disease status and patients' characteristics evaluated at the time of starting daratumumab
therapy. Includes the patient in complete remission with isolated measurable residual …

Allogeneic hematopoietic stem cell transplantation (HSCT) offers potentially curative
treatment for many children with high-risk or relapsed acute leukemia (AL), thanks to the …

Daratumumab (DARA) is an anti-CD38 monoclonal antibody for the treatment of multiple
myeloma (MM). The tumor CD38 expression level is one of the important factors in …

Abstract Purpose of Review Lymphoblastic lymphoma (LBL) is a rare, highly aggressive non-
Hodgkin lymphoma variant virtually indistinguishable from acute lymphoblastic leukemia …